Targeting Differences: Strategies to Demonstrate the Benefits of Novel CNS-active Analgesics

Jack Henningfield, PhD, Vice President, Research, Health Policy, and Abuse Liability, Pinney Associates

David Heal, PhD, DSc, FRSC, FBPhS, Executive Director, DevelRx Ltd.

Reginald Fant, PhD, Director, Clinical Pharmacology and Abuse Potential Assessment

Judy Ashworth, MD, Vice President, Rx Strategic Services and Chief Medical Officer, Pinney Associates

Presented at the 14th Annual Pain Therapeutics Summit, September 21, 2020